Active substance
Results for the substance durvalumab
2 results
About this active substance
Durvalumab is a monoclonal antibody used for the treatment of certain types of cancer, including small cell lung cancer and advanced urothelial carcinoma. It works by blocking the PD-L1 protein, allowing the immune system to recognize and destroy cancer cells.
The medication is administered intravenously, as directed by a doctor, and requires careful monitoring for adverse effects.
Side effects may include fatigue, nausea, diarrhea, skin rash, or injection site reactions. In rare cases, severe immune-related reactions such as pneumonitis or hepatitis may occur.
Durvalumab is not recommended for patients with hypersensitivity to this medication or severe autoimmune conditions.
The medication is administered intravenously, as directed by a doctor, and requires careful monitoring for adverse effects.
Side effects may include fatigue, nausea, diarrhea, skin rash, or injection site reactions. In rare cases, severe immune-related reactions such as pneumonitis or hepatitis may occur.
Durvalumab is not recommended for patients with hypersensitivity to this medication or severe autoimmune conditions.
-
-
IMFINZI 50mg/ml concentrate for solution for infusion ASTRAZENECA ORIGINAL MEDICINE